LLR APC Meeting Minutes May 2025(282 KB) - LMSG/LLR APC minutes
Date added: 4th Jun 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| BARICITINIB (NEW) | Red | For use in monogenic interferonopathies (adults and children 2 years and over) | |
| BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE INHALER (GoResp Digihaler®) | Do not prescribe |
Discontinued June 2024 – see MHRA alert |
|
| CLONIDINE ORAL (NEW) | Yellow | For Tic Disorders including: Chronic Motor Tic Disorder, Chronic Vocal Tic Disorder, Transient Tic Disorder and Tourette Syndrome. Off-label indication | |
| DAPAGLIFLOZIN / METFORMIN (Xigduo®) (UPDATED) | Do not prescribe | Type 2 diabetes |
Not accepted locally for use. Use individual components. |
| DOXEPIN (NEW) | Do not prescribe | Depression |
Not accepted locally for use in depressive illness. Existing patients should be reviewed to an alternative. |
| ENOXAPARIN | Green | Thromboprophylaxis and treatment of DVT and PE |
Prescribe by brand name INHIXA® as different brands have different injection techniques. Courses started during the dalteparin shortage can be continued to be supplied in primary care |
| MULTIVITAMIN AND MINERAL SUPPLEMENT (Forceval) (NEW) | Green |
Restricted for for use in gastric bypass / BPD/DS bariatric surgery on the recommendation of a dietician Restricted for for use in line with the out of hours enteral feeding tube guidelines only Restricted for micronutrient supplementation for patients with intestinal failure |
|
| NEPAFENAC (Nevanac®) | Red | Pain and inflammation post cataract surgery and Cystoid Macular Oedema in Uveitic Patients | |
| OCTEROTIDE (UPDATED) | Yellow | Vomiting in palliative care, initiation by specialist palliative care team only | |
| OCTEROTIDE (UPDATED) | Red |
Multiple indications see Formulary |
|
| PALOPEGTERIPARATIDE (Yorvipath) | Grey |
Review deferred pending NICE outcome. |
|
| RITLECITINIB (Litfulo) | Red | Severe alopecia areata in people 12 years and over |
In line with NICE TA 958.
|
| RITUXIMAB | Red | IgM paraproteinaemic demyelinating peripheral neuropathy in adults | |
| SPF 50+ SUNSCREEN PREPARATIONS (Anthelios) (NEW) | Green | Borderline Substance: only for patients with photosensitive disorder with widespread dysplastic lesions and/or a history of skin cancer |
Restricted Green. Patients should be encouraged to purchase sun screens OTC as per LLR Self-Care Guidelines |
| Tixagevimab plus Cilgavimab | Do not prescribe |
Not recommended, within its marketing authorisation, for treating COVID‑19 as per NICE TA971. |
|
| TOBRAMYCIN inhalation | Red | Cystic fibrosis |
Available as nebuliser solution (Vantobra®, Bramitob®) and dry powder for inhalation (Tobi ® podhaler). |
| USTEKINUMAB | Red | For refractory Crohn’s disease in pre-pubescent children (aged < 6 years old) |
In line with NHSE Clinical Commissioning Policy. |
| VADADUSTAT (Vafseo) (NEW) | Red | Aymptomatic anaemia in adults having dialysis for chronic kidney disease |
Funding from 23/04/2025 |
| VAMOROLONE (Agamree) (NEW) | Red | Duchenne muscular dystrophy in people 4 years and over |
In line with NICE TA1031. |
Other Updates on this Website
Recent documents from LLR APC and TAS
TAS Summaries 2020(44 KB) - TAS
Not produced after February 2020
Date added: 19th May 2025
TAS Summaries 2019(320 KB) - TAS
Date added: 19th May 2025
TAS Summaries 2018(409 KB) - TAS
Date added: 19th May 2025
TAS Summaries 2017(400 KB) - TAS
Date added: 19th May 2025
TAS Summaries 2016(381 KB) - TAS
Date added: 19th May 2025
TAS Summaries 2015(277 KB) - TAS
Date added: 19th May 2025
TAS Annual Report 2019/20(211 KB) - TAS annual report
Date added: 19th May 2025
TAS Annual Report 2016/17(341 KB) - TAS annual report
Date added: 19th May 2025
TAS Annual Report 2017/18(225 KB) - TAS annual report
Date added: 19th May 2025
TAS Annual Report 2018/19(201 KB) - TAS annual report
Date added: 19th May 2025
TAS Annual Report 2020/21(235 KB) - TAS annual report
Date added: 19th May 2025
TAS Annual Report 2022/23(331 KB) - TAS annual report
Date added: 19th May 2025
Ciclosporin Dermatology Shared Care Request Form National Format(353 KB) - Shared care agreement
Version 1 Uploaded December 2022/January 2023
Version 3 uploaded 05/06/2025
Date added: 29th Dec 2022
LLR CCG’s High Cost Drugs List - Guidelines
Document retired June 2025
Date added: 24th Apr 2019
Management of Wheeze in Children Under 5 Years(445 KB) - Guidelines
Updated March 2025
Date added: 4th May 2016
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more